Reliance Life Sciences: IIT Kanpur, Reliance Life Sciences to revolutionise gene therapy for hereditary eye diseases

The gene therapy technology from IIT Kanpur will be further developed as an indigenous product by Reliance Life SciencesIndian Institute of Technology (IIT) Kanpur has licensed a pioneering technology to Reliance Life Sciences that has the potential to revolutionise the field of gene therapy, especially for many genetic eye diseases. There are many inherited disorders caused by faulty genes. This marks the first time that a gene therapy-related technology has been developed and transferred from an academic institution to a company in India. The gene therapy technology from IIT Kanpur will be further developed as an indigenous product by Reliance Life Sciences.The technology licensing agreement was formally signed between IIT Kanpur and Reliance Life Sciences at an MoU exchange ceremony in the presence of several dignitaries, including Prof Abhay Karandikar, Director, IIT Kanpur and KV Subramaniam (Licensee & President of Reliance Life Sciences). Others present on the occasion included Prof Ankush Sharma (PIC, Innovation & Incubation), Prof Amitabha Bandyopadhyay (Head, BSBE Department), Prof Jayandharan Giridhara Rao (Dept. of BSBE), Dr Venkata Ramana (CSO) and Praveen Sharma, GM, Reliance Life Sciences.Developed by Prof Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), ...